LONGBIO-B (01779.HK): Anti-IgE Antibody LP-003 Receives FDA Clinical Trial Clearance for Peanut Allergy
NewTimeSpace News: Longbio-B (01779.HK) announced on 13 July that LP-003, an in-house developed anti-IgE antibody, has obtained clearance from the U.S. FDA to launch clinical trials for peanut allergy. The global food allergy patient population is projected to reach 457 million by 2030. In China, the Company has secured IND approvals or initiated clinical studies of LP-003 across multiple allergic indications. The Company cautions uncertainties exist regarding successful development and commercialisation of the asset.
NewTimeSpace News: On 13 July 2026, Longbio pharma (Suzhou) Co., Ltd. (01779.HK) issued a voluntary announcement stating that the Investigational New Drug (IND) application for self-developed LP-003 for the indication of peanut allergy has been cleared by the U.S. Food and Drug Administration (FDA).
LP-003 is an anti-IgE antibody adopting a novel sequence design. Its core function is to neutralise free IgE in blood and tissues so as to suppress IgE-mediated allergic reactions. IgE serves as the core mediator of Type I hypersensitivity. Anti-IgE therapy has been incorporated into Chinese clinical guidelines for allergic rhinitis and chronic spontaneous urticaria.
Globally, the number of patients suffering from food allergies climbed from 273 million in 2018 to 362 million in 2024, and is expected to hit 457 million by 2030.
Within China, the Company has obtained IND approvals or commenced relevant clinical trials of LP-003 for multiple indications including seasonal allergic rhinitis, chronic spontaneous urticaria, allergic asthma, chronic rhinosinusitis with nasal polyps and food allergy.
The Company reminds investors that there is no guarantee the product can be successfully developed and launched commercially.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
- LONGBIO-B(01779.HK)Rises 37.21% on Listing Day to Close at HK$131.8
- LongBio-B Surges 55.63% on Listing Debut at HK$149.5
- LongBio Pharma(01779.HK): Over-Allotment Option Fully Exercised, Raising Additional Net Proceeds of Approximately HK$194 Million
- LongBio Pharma-B(01779.HK): LP-003 Phase III Trial for Seasonal Allergic Rhinitis Hits Primary Endpoint
